PE20220143A1 - Agonistas de glp-1r y usos de los mismos - Google Patents
Agonistas de glp-1r y usos de los mismosInfo
- Publication number
- PE20220143A1 PE20220143A1 PE2021001694A PE2021001694A PE20220143A1 PE 20220143 A1 PE20220143 A1 PE 20220143A1 PE 2021001694 A PE2021001694 A PE 2021001694A PE 2021001694 A PE2021001694 A PE 2021001694A PE 20220143 A1 PE20220143 A1 PE 20220143A1
- Authority
- PE
- Peru
- Prior art keywords
- membered
- saturated
- ring
- compounds
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripcion proporciona compuestos de Formula (I) o una sal farmaceuticamente aceptable del mismo, en donde: el enlace en el anillo C indica un enlace simple o un enlace doble; X1, X2, X3, X4 y X5 se seleccionan cada uno independientemente de N y CH; W se selecciona de O, S, CR5R6 y NR5'; el anillo B es heteroarilo de 6 miembros, heterociclilo monociclico de 6 miembros o fenilo, en donde Y1 se selecciona de N, NH, CH y CH2; el anillo C es ciclohexilo, fenilo o piridilo; L es CHRd, O, S o NR5'; el anillo D es heteroarilo biciclico; EE es -COOH o un sustituto del grupo carboxilico; cada Ra y Rb se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado, en donde el alquilo C1-C6 o alcoxi C1-C6; cada Rc y Rd se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado; cada R1, R2, R3 y R4 se selecciona o sustituye segun la invencion. Son compuestos preferidos los seleccionados de los compuestos 74-102 y 246-334 o unal sal, estereoisomero, solvato o hidrato farmaceuticamente aceptable del mismo. Tambien se refiere a una composicion farmaceutica y metodos que comprenden el compuesto de la invencion. Dichos compuestos son agonistas del receptor de GLP-1 (GLP-1R) utiles en el tratamiento de diabetes mellitus tipo 2 (T2DM), prediabetes, obesidad, enfermedad del higado graso no alcoholico, esteatohepatitis no alcoholica y enfermedad cardiovascular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019082381 | 2019-04-12 | ||
| PCT/CN2020/084203 WO2020207474A1 (en) | 2019-04-12 | 2020-04-10 | Glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220143A1 true PE20220143A1 (es) | 2022-01-27 |
Family
ID=72750961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001694A PE20220143A1 (es) | 2019-04-12 | 2020-04-10 | Agonistas de glp-1r y usos de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20230278991A1 (es) |
| EP (1) | EP3953344A4 (es) |
| JP (2) | JP7635145B2 (es) |
| KR (2) | KR20260022470A (es) |
| CN (1) | CN113853371B (es) |
| AU (1) | AU2020256647B2 (es) |
| BR (1) | BR112021020335A2 (es) |
| CA (1) | CA3136375A1 (es) |
| CL (1) | CL2021002649A1 (es) |
| CO (1) | CO2021015060A2 (es) |
| CR (1) | CR20210562A (es) |
| CU (1) | CU20210083A7 (es) |
| DO (1) | DOP2021000208A (es) |
| EA (1) | EA202192684A1 (es) |
| IL (1) | IL287128A (es) |
| MA (1) | MA55627A (es) |
| MX (1) | MX2021012492A (es) |
| PE (1) | PE20220143A1 (es) |
| PH (1) | PH12021552557A1 (es) |
| SA (1) | SA521430550B1 (es) |
| SG (1) | SG11202110825WA (es) |
| UA (1) | UA130404C2 (es) |
| WO (1) | WO2020207474A1 (es) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113227068B (zh) | 2018-11-22 | 2023-06-13 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂及其用途 |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| JP7558267B2 (ja) * | 2019-10-25 | 2024-09-30 | ギリアード サイエンシーズ， インコーポレイテッド | Ｇｌｐ－１ｒ調節化合物 |
| US12421205B2 (en) | 2019-12-02 | 2025-09-23 | Hyundai Pharm Co., Ltd. | GLP-1 receptor agonist |
| CN120518596A (zh) | 2020-01-29 | 2025-08-22 | 吉利德科学公司 | Glp-1r调节化合物 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| CN115697999A (zh) * | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| TWI825398B (zh) * | 2020-03-18 | 2023-12-11 | 南韓商Ｌｇ化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
| EP4119555A4 (en) * | 2020-03-18 | 2023-08-23 | Lg Chem, Ltd. | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND PROCESS FOR MANUFACTURE THEREOF |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| PL4143183T3 (pl) | 2020-04-29 | 2026-03-02 | Gasherbrum Bio, Inc. | Heterocykliczni agoniści glp-1 |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| MX2023001311A (es) | 2020-08-06 | 2023-04-18 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
| WO2022042691A1 (en) | 2020-08-28 | 2022-03-03 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464A (zh) | 2020-10-12 | 2023-06-27 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4228753B1 (en) | 2020-10-14 | 2025-07-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN115461334B (zh) * | 2020-11-27 | 2024-06-21 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN115667238B (zh) * | 2020-12-25 | 2024-08-23 | 西藏海思科制药有限公司 | 一种五并五元环衍生物及其在医药上的应用 |
| CN114805336A (zh) * | 2021-01-20 | 2022-07-29 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
| KR20230152011A (ko) * | 2021-01-28 | 2023-11-02 | 카모트 테라퓨틱스, 인크. | Gpcr 수용체 작용제, 이를 포함하는 제약 조성물, 및 그 사용 방법 |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022199458A1 (zh) | 2021-03-22 | 2022-09-29 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| CN117222631A (zh) * | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| EP4582421A3 (en) * | 2021-04-08 | 2025-10-01 | LG Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| WO2022216094A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| BR112023021108A2 (pt) * | 2021-04-12 | 2023-12-12 | Novartis Ag | Derivados de 2-((4-((s)-2-(4-cloro-2-fluorofenil)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-imidazol como ativadores do receptor de glp1 para o tratamento de obesidade |
| CN117279905A (zh) * | 2021-04-21 | 2023-12-22 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| AU2022260487B2 (en) * | 2021-04-21 | 2025-08-28 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| IL306110A (en) * | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| MX2023012918A (es) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics Inc | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso. |
| CN117355517A (zh) * | 2021-05-20 | 2024-01-05 | 伊莱利利公司 | 大环胰高血糖素样肽1受体激动剂 |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| AU2022300055A1 (en) * | 2021-06-24 | 2024-01-18 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1 receptor agonist and composition and use thereof |
| JP2024525900A (ja) * | 2021-07-21 | 2024-07-12 | ヘパジーン セラピューティクス（エイチケー）リミティド | グルカゴン様ペプチド－１受容体モジュレーター及びその使用 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| CN118215478A (zh) | 2021-09-08 | 2024-06-18 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| LT4408840T (lt) | 2021-09-27 | 2025-10-10 | Benzimidazolo karboksilinės rūgštys kaip glp-1r agonistai | |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| US20250154161A1 (en) * | 2021-12-03 | 2025-05-15 | Hangzhou Sciwind Biosciences Co., Ltd. | Crystal forms of thienoimidazole compound and preparation method thereof |
| WO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体 |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| CN118613476A (zh) * | 2022-01-10 | 2024-09-06 | 西藏海思科制药有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| IL315275A (en) * | 2022-02-28 | 2024-10-01 | Ascletis Bioscience Co Ltd | Glp-1r modulating compounds |
| US20230271949A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| JP2025508097A (ja) | 2022-03-08 | 2025-03-21 | 広州市聯瑞制葯有限公司 | ベンゾビシクロ系化合物及びその製造方法と応用 |
| CA3249144A1 (en) * | 2022-05-20 | 2025-06-17 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, ITS PREPARATION PROCESS AND ITS USE |
| CN119731181A (zh) * | 2022-06-23 | 2025-03-28 | 西藏海思科制药有限公司 | 一种噻吩[2,3-d]咪唑类化合物的盐及其晶型和在医药上的用途 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| JP2025530809A (ja) * | 2022-09-06 | 2025-09-17 | 徳睿智薬（蘇州）新薬研発有限公司 | Ｇｌｐ－１ｒアゴニスト化合物の結晶多形物及びその製造方法と使用 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| WO2024125442A1 (zh) * | 2022-12-13 | 2024-06-20 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的新晶型和制备方法及其药物组合物和用途 |
| CN116082321A (zh) * | 2022-12-23 | 2023-05-09 | 华中药业股份有限公司 | 一种咪唑并芳杂基类衍生物、药物组合物及其应用 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| KR20250125490A (ko) * | 2024-02-14 | 2025-08-22 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2262364B1 (en) | 2008-03-07 | 2016-03-02 | vTv Therapeutics LLC | Oxadiazoanthracene compounds for the treatment of diabetes |
| SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| RU2634896C2 (ru) | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| RU2765721C1 (ru) * | 2018-06-15 | 2022-02-02 | Пфайзер Инк. | Агонисты glp-1 рецептора и их применение |
| CN113227068B (zh) * | 2018-11-22 | 2023-06-13 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂及其用途 |
| JP7558267B2 (ja) * | 2019-10-25 | 2024-09-30 | ギリアード サイエンシーズ， インコーポレイテッド | Ｇｌｐ－１ｒ調節化合物 |
| US12421205B2 (en) * | 2019-12-02 | 2025-09-23 | Hyundai Pharm Co., Ltd. | GLP-1 receptor agonist |
| CN115697999A (zh) * | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
-
2020
- 2020-04-10 PH PH1/2021/552557A patent/PH12021552557A1/en unknown
- 2020-04-10 AU AU2020256647A patent/AU2020256647B2/en active Active
- 2020-04-10 KR KR1020267001628A patent/KR20260022470A/ko active Pending
- 2020-04-10 JP JP2021560022A patent/JP7635145B2/ja active Active
- 2020-04-10 MA MA055627A patent/MA55627A/fr unknown
- 2020-04-10 WO PCT/CN2020/084203 patent/WO2020207474A1/en not_active Ceased
- 2020-04-10 BR BR112021020335A patent/BR112021020335A2/pt unknown
- 2020-04-10 EA EA202192684A patent/EA202192684A1/ru unknown
- 2020-04-10 CR CR20210562A patent/CR20210562A/es unknown
- 2020-04-10 PE PE2021001694A patent/PE20220143A1/es unknown
- 2020-04-10 MX MX2021012492A patent/MX2021012492A/es unknown
- 2020-04-10 KR KR1020217036543A patent/KR102915918B1/ko active Active
- 2020-04-10 CA CA3136375A patent/CA3136375A1/en active Pending
- 2020-04-10 CN CN202080028229.XA patent/CN113853371B/zh active Active
- 2020-04-10 UA UAA202106216A patent/UA130404C2/uk unknown
- 2020-04-10 EP EP20788321.6A patent/EP3953344A4/en active Pending
- 2020-04-10 CU CU2021000083A patent/CU20210083A7/es unknown
- 2020-04-10 SG SG11202110825WA patent/SG11202110825WA/en unknown
-
2021
- 2021-10-08 CL CL2021002649A patent/CL2021002649A1/es unknown
- 2021-10-10 IL IL287128A patent/IL287128A/en unknown
- 2021-10-11 SA SA521430550A patent/SA521430550B1/ar unknown
- 2021-10-11 DO DO2021000208A patent/DOP2021000208A/es unknown
- 2021-11-08 CO CONC2021/0015060A patent/CO2021015060A2/es unknown
-
2023
- 2023-02-24 US US18/113,859 patent/US20230278991A1/en not_active Abandoned
-
2024
- 2024-09-10 US US18/830,194 patent/US20250042883A1/en active Pending
-
2025
- 2025-02-10 JP JP2025019723A patent/JP2025072577A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CU20210083A7 (es) | 2022-05-11 |
| JP2022527607A (ja) | 2022-06-02 |
| SG11202110825WA (en) | 2021-10-28 |
| AU2020256647A1 (en) | 2021-11-18 |
| MX2021012492A (es) | 2021-11-12 |
| CO2021015060A2 (es) | 2021-11-19 |
| JP7635145B2 (ja) | 2025-02-25 |
| EP3953344A1 (en) | 2022-02-16 |
| CN113853371B (zh) | 2024-05-03 |
| EA202192684A1 (ru) | 2021-12-28 |
| EP3953344A4 (en) | 2023-08-09 |
| DOP2021000208A (es) | 2021-11-21 |
| US20250042883A1 (en) | 2025-02-06 |
| WO2020207474A1 (en) | 2020-10-15 |
| IL287128A (en) | 2021-12-01 |
| BR112021020335A2 (pt) | 2021-12-14 |
| JP2025072577A (ja) | 2025-05-09 |
| KR102915918B1 (ko) | 2026-01-22 |
| CL2021002649A1 (es) | 2022-05-06 |
| CA3136375A1 (en) | 2020-10-15 |
| PH12021552557A1 (en) | 2022-07-04 |
| KR20260022470A (ko) | 2026-02-19 |
| US20230278991A1 (en) | 2023-09-07 |
| SA521430550B1 (ar) | 2025-04-14 |
| KR20210152513A (ko) | 2021-12-15 |
| CN113853371A (zh) | 2021-12-28 |
| UA130404C2 (uk) | 2026-02-11 |
| MA55627A (fr) | 2022-02-16 |
| AU2020256647B2 (en) | 2025-07-31 |
| CR20210562A (es) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| PE20211871A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR076551A1 (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR056548A1 (es) | Derivados de sulfonamidas, composiciones farmaceuticas y sus usos | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| ES2929140T3 (es) | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| CL2018000036A1 (es) | Derivados etinilo | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| PE20090218A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR076219A1 (es) | Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR053548A1 (es) | Derivados de oxiindol | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
| AR061656A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto |